Articles tagged with Chemotherapy
Researchers at Imperial College London conducted a clinical trial using immunotherapy drug pembrolizumab on four patients with multi-drug resistant GTD. The study found that three out of four patients went into remission, with no signs of cancer recurrence for between five months to over two years.
Researchers discovered that these antimalarial drugs make tumour cells more sensitive to cancer treatment, suggesting potential benefits for certain cancer patients. The findings have sparked excitement among scientists, who are now eagerly awaiting the results of ongoing clinical studies.
Researchers found that breast cancer tumors impair learning and memory in mice before chemotherapy, suggesting cancer progression causes 'chemo brain' symptoms. After chemotherapy, cancer and drug therapy contribute to cognitive impairment.
A new data mining approach has identified the key publications that drove the development of five major anti-cancer drugs, revealing the importance of research collaboration, grants, and publications in breakthroughs. The study's findings have implications for research institutions planning collaborative efforts.
A Cornell study reveals that testicular cancer's responsiveness to chemotherapy is due to its stem cells, which are more sensitive to treatment. The research provides new insights into the basis for this phenomenon and may lead to better treatments for other cancers.
A report by the University of Birmingham calls for policymakers to focus on measurable objectives and simple language in their action plans. The current EU and UK plans have been criticized for lacking specificity and consistency, making it difficult to track progress and evaluate success.
Researchers have developed a method to grow hundreds of lab-grown cancer spheroids from just a few tumor cells derived from a patient. These 3-D cultured cells can accurately mirror the response of natural cells implanted in mice, making them a potential tool for testing individualized treatments.
Researchers found that adipocytes can metabolize daunorubicin, making it less toxic to leukemia cells. This discovery highlights the need for new chemotherapy strategies that are resistant to fat cell enzymes.
Cells can sense and mend damaged DNA caused by certain chemotherapy drugs. Researchers discovered a previously unknown repair complex that targets this type of damage. This finding could lead to more effective chemotherapy treatments by amplifying the killing power of existing drugs.
Researchers developed a targeted approach to immunotherapy by conjugating cancer drugs to peptides that bind to tumor tissues. This method showed promise in mice models, improving efficacy while minimizing treatment-related side effects.
Researchers at Scripps Research Institute have discovered a compound that irreversibly stops the growth of certain aggressive, treatment-resistant tumor cells. The compound, FiVe1, blocks cell division by binding to a structural protein, vimentin, produced abundantly in mesenchymal-type cells.
RUDN University scientists have discovered a new formation mechanism for anti-cancer substances, which can be used to synthesize organophosphorus compounds with specified properties. The researchers found that the reaction does not proceed according to the previously thought Michaelis-Arbuzov reaction mechanism, but rather another way.
Researchers have successfully tested a new molecule capable of preventing peripheral neuropathy induced by chemotherapy in cancer patients. The molecule has shown positive results in reducing the appearance of disorders associated with nerve dysfunction.
A study published in JNCI Journal of the National Cancer Institute found that cryotherapy can prevent symptoms of chemotherapy-induced peripheral neuropathy, improving quality of life for cancer patients. Cryotherapy involves wearing frozen gloves and socks during chemotherapy to reduce pain, numbness, and tingling.
Researchers successfully deliver platinum-based chemotherapy drugs via nanoparticles to treat nonmuscle-invasive bladder cancer, reducing systemic absorption and toxicity. The study offers a potential less toxic clinical alternative to standard chemotherapy.
Researchers at Dana-Farber Cancer Institute discovered a protein called Bclw that protects nerves from degeneration. Adding Bclw to nerve axons before exposure to chemotherapy drugs may prevent peripheral neuropathy symptoms.
International experts have identified a new protein called ZATT that can directly clean DNA breaks without degradation, allowing for more efficient repair and potentially increasing chemotherapy sensitivity. This breakthrough has the potential to improve treatment outcomes and enable personalized therapies.
Researchers in Brazil are testing a technique combining low-intensity electric current with nanoencapsulated chemotherapy to treat skin cancer. The study found that topical application combined with iontophoresis resulted in a significantly greater reduction in tumor size and made the tumor less aggressive.
A recent study by Tal Danino at the Data Science Institute demonstrates that bacteria in pancreatic tumors degrade a chemotherapy drug, Gemcitabine. The study found that antibiotics were effective in killing these bacteria in over 70% of mice, leading to rapid tumor progression without treatment.
A laboratory-based study discovered that an alcohol aversion drug can reverse chemotherapy resistance in non-small cell lung cancer. The researchers found that the drug, Disulfiram, inhibited ALDH activity, reducing tumour cell growth and killing lung cancer stem cells.
Research led by Dr. Carlos Arteaga has identified potential targets for treating chemotherapy-resistant triple negative breast cancer, including genes MCL1 and MYC. These genes can be targeted with specific drugs to slow or prevent chemotherapy resistance, improving the outlook for this aggressive form of breast cancer.
Cancer survivors experience significant cognitive impairment due to chemotherapy, which can impact multitasking, memory and concentration. Researchers are developing strategies to prevent this condition without reducing chemotherapy efficacy, aiming to improve quality of life for millions of cancer patients.
Scientists at NGM Bio have uncovered the molecular biology and mechanisms of Growth and Differentiation Factor 15 (GDF15), a hormone regulating body weight. The study reveals potential therapeutics for diseases of excess and insufficient body weight, including obesity and cachexia.
Research shows carbidopa, an FDA-approved Parkinson's disease drug, has anticancer properties. The study found that carbidopa significantly inhibits cancer cell growth in both human pancreatic cancer cells and mouse models, suggesting potential as an anticancer medication.
The study found that four fractions of 7 Gy HDR brachytherapy resulted in significantly better tumor control than two 9-Gy fractions, with a higher survival rate for women with stage IIB disease. Severe treatment-related side effects did not differ significantly between treatment arms.
A randomized phase II clinical trial found that adding consolidative stereotactic radiation therapy to chemotherapy significantly increased progression-free survival expectancy nearly tripling it for patients with limited metastatic disease. Treatment-related side effects were similar between the two treatment approaches.
Researchers identified a new genetic syndrome caused by biallelic mutations in the FANCM gene, leading to early cancer formations and chemotherapy toxicity. Patients with this syndrome did not develop Fanconi anaemia, but had a higher risk of breast cancer and chromosomal fragility.
Researchers discover bacteria in pancreatic tumors that metabolize a common chemotherapy drug, rendering it ineffective. The study suggests that targeting these bacteria may offer a new approach to treating pancreatic cancer.
A recent study published in Journal of Pineal Research found that melatonin can prevent nerve damage caused by chemotherapy and reduce painful side effects. The drug was shown to limit the damaging effect on nerve cells and the development of pain symptoms when given prior to chemotherapy.
Researchers have developed a novel technique to deliver steroids directly into the cochlea, reducing hearing loss caused by cisplatin treatment in mice by 50%. This breakthrough has potential applications for treating various types of hearing loss and could also be used to deliver other drugs and therapies.
The KEYNOTE-040 trial found that pembrolizumab significantly improved outcomes in patients with recurrent or metastatic head and neck squamous cell carcinoma, especially those with high PD-L1 expression. The study also showed a better side-effect profile for pembrolizumab compared to standard treatments.
A recent ESMO 2017 Congress session has ignited debate on the optimal duration of adjuvant chemotherapy for colon cancer, with experts weighing in on the pros and cons of shortening treatment from six to three months. The IDEA study suggests that three months provides a similar benefit but with reduced side effects.
The KEYNOTE-045 trial demonstrates pembrolizumab's superiority in overall survival and adverse event profile compared to chemotherapy in platinum-pretreated urothelial cancer patients. The medication offers durable responses and a favorable safety profile.
A randomized trial of over 600 patients confirms chemoradiation as the standard treatment for locally advanced cervical cancer, with no improved disease-free survival seen with neoadjuvant chemotherapy followed by surgery. The findings suggest that chemoradiation should remain the standard treatment.
A study presented at ESMO 2017 found that socio-psychological factors, such as anxiety and family concerns, are now more significant for cancer patients than previously thought. The study suggests that doctors should consider improving supportive therapies and providing stronger psychological support to address these issues.
Recent phase 3 studies (ALEX and ALUR trials) demonstrate alectinib's efficacy in treating non-small cell lung cancer (NSCLC) with central nervous system (CNS) involvement. The medication significantly decreases CNS progression, improving median progression-free survival by up to 8 months compared to standard chemotherapy.
A recent study found that nearly one in four small tumours were aggressive and patients benefited from chemotherapy. Researchers identified a 70-gene signature to detect aggressive tumours.
Researchers at Cornell University have identified a potential solution to protect premenopausal women from life-altering infertility after cancer treatment. By inhibiting the checkpoint pathway, the study found that oocytes survived radiation and remained fertile, enabling birth of healthy pups.
Researchers at the Francis Crick Institute found that acute myeloid leukemia causes bone marrow to 'leak' blood, preventing chemotherapy from working. Drugs that reversed this leakiness boosted chemotherapy's effect in mice and human tissue.
Researchers found that combining CDKs' inhibitors with conventional anti-cancer drugs like cisplatin increases tumor cell death. However, treating cells with 5-FU can lead to decreased death rates and resistance. This study suggests a promising approach for developing new anti-cancer treatments.
Researchers have developed a method that targets cancerous tumors with chemotherapy, delivering the drug directly to cancer cells while protecting healthy cells. The treatment uses nanoparticles and ultrasound to improve delivery, showing promising results in mice experiments.
Researchers develop model using zebrafish larvae to predict personalized treatment of cancer, offering faster and safer option than current methods. The study confirms that zebrafish and mice react similarly to treatments, enabling timely answers in under two weeks.
Researchers discovered that combining a novel drug MI-773 with traditional chemotherapy cisplatin destroyed salivary gland tumor cells and prevented recurrence within 300 days. This combination therapy showed promise in treating adenoid cystic carcinoma, a rare cancer affecting 3,000-4,000 people annually.
Future medications can be scaled up using electrochemistry, creating vicinal diamines without toxic waste. This process employs Earth-abundant manganese, offering a more sustainable alternative to traditional chemical synthesis methods.
A new hybrid biomaterial delivers a chemotherapeutic agent and RNA interfering technology to silence drug resistance, resulting in substantial decrease in cancer cell viability. The material's ease of modification allows for swapping out components to suit specific cell lines and drugs.
Researchers identified synthetic lethal interactions that inhibit tumor growth in mesenchymal cells, a promising approach for treating alternative lengthening telomere (ALT) cancers. Simultaneous inhibition of BLM and FANCM genes could lead to more effective treatment with fewer side effects.
Researchers at Tokyo Medical and Dental University identified two microRNAs that can improve pancreatic cancer response to gemcitabine, a common chemotherapy drug. These findings suggest novel combined treatments for this devastating disease. MicroRNA levels can also predict prognosis in pancreatic cancer patients.
Researchers found that Fusobacterium nucleatum in the gut can stop chemotherapy from causing apoptosis, a type of cancer cell death. The bacterium activates autophagy, a cell-survival mechanism that protects cancer cells from destroying themselves.
A Berlin study of patients with early-stage colon cancer has found that the MACC1 gene and DNA repair mechanisms can help determine prognosis and predict response to chemotherapy. Patients with low MACC1 levels and proficient mismatch repair status have a higher five-year survival rate.
Research found that four molecular subtypes of gastric cancer have different prognoses and responses to chemotherapy, with the EBV subtype associated with the best outcome and the GS subtype with no benefit. The study suggests that classifying gastric cancer cases by subtype could provide personalized treatment options.
Researchers found that cancer patients who interacted with other patients undergoing chemotherapy were more likely to survive for five years or more after treatment. The study suggests a possible link between social interaction and stress response in the context of cancer treatment.
TAK228 enhances radiation and chemotherapy for diffuse intrinsic pontine glioma (DIPG) and atypical teratoid/rhabdoid tumors (AT/RT), two childhood brain cancers with poor prognosis. The drug reduces tumor cell proliferation and increases cancer cell death, particularly when combined with treatment.
Three case reports published in NEJM demonstrate the efficacy of cancer immunotherapy in gray zone lymphoma, a rare subtype of Hodgkin and Non-Hodgkin forms of the disease. Nivolumab and pembrolizomab showed promising results in treating patients with PD-L1 over-expression.
Researchers at the University of Cambridge have developed a new statistical model to estimate kidney function in cancer patients, improving chemotherapy dosing accuracy. The model reduces errors from over 20% to 11.7% compared to existing methods.
Patients with right-sided primary tumours have a 36% better survival rate after treatment with a combination of first-line chemotherapy and selective internal radiation therapy, compared to chemotherapy alone. This treatment combination was no better than chemotherapy only in patients with left-sided primary tumours.
The University of Texas at Arlington has awarded three new seed grants for interdisciplinary research projects addressing skin cancer, rapid drug evaluation and mental health risks among homeless youth. The projects aim to develop innovative treatments and programs using cutting-edge technology.
A recent study by researchers at Case Western Reserve University has discovered that injecting potato virus particles into melanoma tumors activates an anti-tumor immune response, halting tumor progression. Co-administering the nanoparticles with chemotherapy drugs yields the most potent benefit.
Researchers developed micro-cubes that can sponge up a hydrophobic anti-cancer drug and deliver it to cancer cells, showing increased potency against liver cancer cells and reduced harm to normal liver cells. The cubes retain their shape and release the drug in response to higher redox potentials found in cancer cells.
A team of researchers has discovered that a DNA-cutting enzyme plays a broad role in driving abnormal genetic rearrangements, including translocations that cause cancer. The study identified specific sites of DNA damage along the entire genome of human leukemia cells.
Researchers created a system that uses continuous flow technology to produce pharmaceutical compounds, improving safety and yield. The new approach yielded 24 kilograms of chemotherapy agent prexasertib over three days, demonstrating its effectiveness.